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ABSTRACT 
Atrial Fibrillation (AF) is an arrhythmia characterized by disorganization of atrial depolarization 
resulting in the impaired mechanical function of the atrium. Management of AF aims to prevent 
complications of ischemic stroke and systemic embolism, carried out by the administration of 
anticoagulant, warfarin, but warfarin has many side effects. New Oral Anticoagulants (NOAC) can be 
used as alternatives in preventing complications of AF.New anticoagulants such as dabigatran, 
rivaroxaban, and apixaban have better effects than other anticoagulants such as warfarin and have 
major side effects of bleeding and minimal relevant bleeding. Based on a national survey in Denmark 
to see a balance between stroke and intracranial bleeding, CHA2DS2-VASc 1 scores were only 
apixaban and both dabigatran doses (110 mg bid and 150 mg bid) which provided better clinical 
benefits than warfarin, but if the CHA2DS2- score VASc ≥2 of all NOACs is superior to warfarin. 
Atrial fibrillation can cause ischemic stroke and systemic embolism. New Oral Anticoagulant 
(NOACs) can be used as a solution to prevent complications from AF with minimal side effects. It is 
expected that the presence of new anticoagulants can reduce the rate of ischemic stroke and ischemic 
embolism due to AF with minimal side effects of bleeding and other side effects. 
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ABSTRAK 
Atrial Fibrilasi (AF) adalah suatu aritmia yang ditandai dengan disorganisasi dari depolarisasi 
atrium sehingga berakibat pada gangguan fungsi mekanik atrium. Penatalaksanaan AF bertujuan 
mencegah komplikasiyakni stroke iskemik dan emboli sistemik, dilakukan dengan cara pemberian 
anti-koagulan yakni warfarin. Pemberian warfarin  memiliki banyak efek samping. Novel Oral Anti 
Coagulants (NOAC) dapat dijadikan alternatif  dalam mencegah komplikasi AF. Anti-koagulan baru 
seperti dabigatran, rivaroxaban dan apixaban memiliki efektifitas yang lebih baik daripada anti-
koagulan lainnya seperti warfarin dan memiliki efek samping perdarahan mayor dan perdarahan 
relevan yang minimal. Berdasarkan survei nasional di Denmark untuk melihat keseimbangan antara 
stroke dan perdarahan intra-kranial didapatkan bila skor Congestive heart failure, Hypertension, 
Age ≥75 years (skor 2), Diabetes mellitus, Stroke history (skor 2), peripheral Vascular disease, Age 
between 65 to 74 years, Sex Category (female) dan “C” adalah adanya disfungsi ventrikel kiri 
sedang hingga berat (Left Ventricular Ejection Fraction/LVEF ≤ 40%)  CHA2DS2-VASc  1 hanya 
apixaban dan kedua dosis dabigatran (110 mg b.i.ddan 150 mg b.i.d) yang memberikan manfaat 
klinis yang lebih baik daripada warfarin, tetapi apabila skor CHA2DS2-VASc ≥2 seluruh NOAC lebih 
superior dibanding warfarin.AF dapat menyebabkan stroke iskemik dan emboli sistemik.NOAC dapat 
dijadikan solusi untuk mencegah komplikasi dari AF dengan efek samping yang minimal. Diharapkan 
dengan hadirnya anti-koagulan baru dapat menurunkan angka stroke iskemik dan emboli iskemik 
akibat AF dengan efek samping perdarahan dan efek samping lainnya yang minimal. 
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      Atrial Fibrillation (AF) is an 
arrhythmia characterized by disorgani-
zation of atrial depolarization resulting in 
impaired atrial mechanical function. In 
electrocardiography (ECG) the picture of 
AF is characterized by the alternation of P 
waves by fibrillation or fast oscillation 
waves that vary in shape, amplitude or 
interval, followed by irregular ventricular 
responses, while atrio-ventricular (AV) 
conduction is still intact.[1] 
      AF is an arithmetic that is most often 
found in daily medical practice. The 
prevalence of AF reaches 1-2% and will 
continue to increase in the next 50 years. A 
study involving 5209 healthy research 
subjects (not suffering from cardiovascular 
disease) showed that in a 20-year period, 
the incidence of AF was 2.1% in males 
and 1.7% in females. In Indonesia, there 
was a significant increase in the 
percentage of the elderly population in 
Indonesia, namely 7.74% in the 2000-2005 
range to 28.68% in the 2045-2050 range, 
so the incidence of AF would also increase 
significantly.[1,2] 
      AF has varied clinical symptoms, the 
most common is palpitations. Other 
symptoms that are often found in the form 
of pre-syncope, weakness, dyspnea, 
dizziness and chest pain. Some patients 
with atrial fibrillation do not show typical 
symptoms of atrial fibrillation. Definitive 
diagnosis of AF is done using ECG. In 
ECG, the characteristic of AF is the 
absence of consistency of P waves, which 
are replaced by vibrational waves 
(fibrillation) which vary in amplitude, 
shape and duration. In normal atrio-
ventricular (NAV) function, AF is usually 
followed by a ventricular response that is 
also irregular, and often fast.[1,2]       
      The risk of ischemic stroke and 
systemic embolism in patients with AF is 
based on a number of pathophysiological 
mechanisms, ie blood flow abnormalities 
characterized by static blood flow in the 
left atrium will cause a decrease in flow 
velocity in the left atrial auricle which can 
be seen as spontaneous echo-contrast on 
echocardiography.[3] 
      The management of AF aims to avoid 
complications that can occur, namely 
reducing the risk of ischemic stroke and 
other systemic emboli. In general the risk 
of stroke in AF is 15% per year which is 
around 1.5% in the 50 to 59 years age 
group and increases to 23.5% in the 80 to 
89 years age group. While the average 
incidence of strokes and other systemic 
emboli is 5% (around 3-4%).[1,3] 
      Management given to AF patients is 
anti-thrombotic therapy that is used for 
stroke prevention in AF patients including 
anticoagulants and antiplatelets. Vitamin K 
antagonists (warfarin or coumadin) are the 
most widely used anticoagulant drugs for 
the prevention of strokes in AF. Although 
it has been used for a long time, warfarin 
therapy is definitely difficult to administer, 
because warfarin has a narrow therapeutic 
index, side effects and many metabolic 
variations that are difficult to estimate and 
usually require dose adjustments. For this 
reason alternative therapies are needed as 
anticoagulants which have effective work 
and minimal side effects. Novel Oral Anti 
Coagulants (NOACs) can be an alternative 




      AF causes increased mortality and 
morbidity, including stroke, heart failure 
and decreased quality of life. Patients with 
AF have a risk of stroke 5 times higher and 
the risk of heart failure 3 times higher than 
patients without AF. Stroke is one of the 
most worrying complications of AF, 
because strokes caused by AF have a 
higher risk of recurrence. In addition, 
stroke due to AF resulted in death doubled 
and 1.5 times the cost of treatment.[1,3,4] 
      AF with other cardiovascular diseases 
such as hypertension, heart failure, 
coronary heart disease, hyperthyroidism, 
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disease such as atrial septal defects, 
cardiomyopathy, chronic kidney disease 
and chronic obstructive pulmonary disease 
(COPD). Symptomatic heart failure with 
functional class New York Heart 
Association (NYHA) II to IV can occur in 
30% of patients with AF, but conversely 
AF can occur in 30-40% of patients with 
heart failure depending on the cause of 
heart failure. AF can cause heart failure 
through a mechanism of increased atrial 
pressure, increased cardiac volume load, 
valve dysfunction and chronic neuro 
hormonal stimulation. Distention in the 
left atrium can cause AF as occurs in 
patients with heart valve disease with a 
prevalence of 30% and 10-15% in the 
atrial septal effect. About 20% of the 
population of AF patients have coronary 
heart disease, although the link between 
AF itself and coronary perfusion is 
unclear.[2-4] 
      The management of AF aims to 
prevent complications. Antithrombotic 
therapy is the first choice used for 
prevention of stroke caused by AF. Anti-
thrombotic therapies used for stroke 
prevention in AF patients include 
anticoagulants and antiplatelets. Another 
type of anti-thrombotic, thrombolytic, is 
not used for stroke prevention in patients 
AF.[1,3,4] 
      Vitamin K antagonists (AVK) such as 
warfarin and coumadin are the most 
widely used anticoagulant drugs to prevent 
strokes in AF. AVK such as warfarin plays 
a role in blood clotting, causing 
depletifactors II, VII, IX and X. Warfarin 
works in the liver by inhibiting the 
carboxylation of vitamin K from its 
precursor protein. The antithrombotic 
effect of AVK is only effective if there is a 
depletion of these four factors. This results 
in AVK taking several days to be effective 
as an anticoagulant. In addition, the use of 
AVK has many side effects in the form of 
bleeding. Five studies conducted by 
comparing AVK with placebo found that 
the major hemorrhage rate due to AVK 
was 1.3% per year compared to only 1% 
on placebo. Other additional evidence is 
that AVK is only effective as a stroke 
prevention when the time in therapeutic 
range (TTR) is 70%. TTR is the proportion 
of time when an International normalized 
ratio (INR) of 2-3 is reached compared to 
the overall length of time consuming 
AVK. This difficulty is compounded by 
the unavailability of INR inspection 
facilities in peripheral areas in Indonesia. 
Besides bleeding, AVK also has other side 
effects namely skin and tissue necrosis, 
alopecia, urticaria, dermatitis and can be 
hypersensitivity. Because of the side 
effects caused by AVK, New oral 
anticoagulants (NOACs) are needed with 
minimal side effects but have the same 
effectiveness as AVK.[4,5]       
      At present, in Indonesia there are 3 
types of NOACs that exist in Indonesia 
that are not AVK, yakni dabigatran, 
rivaroxaban and apixaban.[3,5,6] 
 
Dabigatran Etexilate 
      Dabigatran are NOACs which directly 
inhibit thrombin. The RE-LY (Randimized 
Evaluation of Long-term anticoagulant 
therapist Y with dabigatran etexilate) study 
compared the dose of dabigatran etexilate 
with adjusted dose warfarin. For primary 
efficacy endpoints in the form of stroke 
and systemic embolism, dabigatran given 
at a dose of 150 mg b.i.d found that 
dabigatran was superior to warfarin, 
without significant differences in the 
primary safety endpoint in the form of 
major bleeding. Hemorrhagic stroke and 
intracranial hemorrhage rates are lower in 
dabigatran compared to warfarin and have 
a lower risk of major bleeding than 
warfarin. Based on the results of the RE-
LY study, dabigatran etexilate has been 
approved by the drug authorities of several 
countries in Europe such as the Food and 
Drug Administration (FDA) and the 
European Medicines Agency (EMA). The 
EMA determines the use of dabigatran for 
non-valvular AF with at least one of the 
following risk factors: history of stroke, 
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embolism, LVEF <40%, symptomatic 
heart failure and age ≥75 years or ≥65 
years but accompanied by one of the risk 
factors such as diabetes, coronary heart 
disease or hypertension. The FDA 
approves a dose of 150 mg b.i.d and a dose 
of 75 mg b.i.d in the event of severe renal 
impairment, while the EMA approves a 
dose of 110 mg b.i.d or 150 mg b.i.d.[3-5] 
 
Rivaroxaban 
      Rivaroxaban works by directly 
inhibiting factor Xa. A study comparing 
the use of rivaroxaban with a dose of 20 
mg o.d. (15 mg o.d. when creatinine 
clearance count is 39-49 ml / min) 
compared with warfarin in 14264 high-risk 
AF patients. From the results of the study 
found no decrease in mortality or ischemic 
stroke but there is a significant decrease in 
hemorrhagic stroke and intracranial 
hemorrhage. There was no difference in 
the primary safety endpoint that was a 
combination of major bleeding and 
clinically relevant bleeding but there was a 
decrease in fatal bleeding in the 
rivaroxaban group. Rivaroxaban has also 
been approved by the FDA and EMA for 
stroke prevention in non-valvular AF.[1,4-6] 
 
Apixaban 
      A study was conducted on 5599 AF 
patients who were not suitable for AVK 
therapy given apixaban (5 mg bid with 
adjusted dose to 2.5 mg bid when age ≥80 
years old, body weight ≤60 kg or serum 
creatinine ≥1.5 mg / dL ) or given aspirin 
(81-324 mg / day with 91% drinking ≤162 
mg / day). After a 1.1-year observation 
period, the study was terminated earlier 
because there was a significant reduction 
of 55% in the primary endpoint in the form 
of a stroke or systemic embolism in the 
apixaban group compared with aspirin, 
with no difference in the incidence of 
major and intracranial hemorrhage. 
Apixaban is better tolerated than aspirin 
with a drug withdrawal rate of 17.9% 
compared to aspirin which reaches 
20.5%.[4-6]       
      Meanwhile another study compared 
apixaban [5 mg bid with dose adjustment 
to 2.5 mg bid if ≥80 years old, body 
weight ≤60 kg or with serum creatinine 
≥1.5 mg / dl (133 mmol / L)] with warfarin 
dose adjusted to obtain a value of INR 2-3 
in 18201 non-valvular AF patients. There 
was a significant reduction in primary 
efficacy outcomes in the form of stroke or 
ischemic embolism of up to 21% in the 
apixaban group compared to warfarin, a 
31% reduction in the incidence of major 
bleeding and a significant 11% reduction 
in all-cause mortality. The incidence of 
hemorrhagic stroke and intracranial 
hemorrhage is significantly lower in the 
apixaban group but not so for ischemic 
stroke. Apixaban was better tolerated than 
warfarin with little early discontinuity 
(25.3% vs 27.5%). Apixaban has also 
received EMA and FDA approval for 
indications of stroke prevention in non-
valvular AF.[2,3,8] 
      New anticoagulant drugs are proven to 
be non-inferior to warfarin with better 
safety. On this basis NOACs are preferred 
over warfarin in the majority of non-
valvular AF patients. There are no further 
studies that compare among NOACs, but 
in terms of major hemorrhage rates of 
dabigatran 110 mg b.i.d and apixaban are 
lower than other NOACs.[8,9] 
      Based on a national survey in Denmark 
to see the balance between stroke and 
intracranial hemorrhage obtained only 
apixaban and both dabigatran doses (110 
mg b.i.d and 150 mg b.i.d) which provide 
better clinical benefits than warfarin.[5,7,8] 
 
 
     Atrial Fibrillation (AF) is an arrhythmia 
characterized by disorganization of atrial 
depolarization resulting in impaired atrial 
mechanical function. AF can cause 
ischemic strokes and systemic embolism. 
Prevention of the occurrence of ischemic 
stroke and systemic embolism is done by 
administering anti-coagulants such as 
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But warfarin has several dangerous side 
effects such as can cause bleeding. For this 
reason, another alternative is needed to 
prevent ischemic stroke and systemic 
embolism with minimal side effects.Novel 
Oral Anti Coagulants (NOACs) can be 
used as a solution to prevent complications 
from AF with minimal side effects. In 
Indonesia at this time, circulating 3 types 
of NOACs namely dabigatran, rivaroxaban 
and apixaban which have better 
effectiveness than warfarin with minimal 
bleeding side effects. 
 
 
      It is expected that the presence of 
NOACs can reduce the number of 
ischemic strokes and ischemic embolism 
due to AF with side effects of bleeding and 
other side effects. 
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